Company profile / ARWR
Commercial-stage RNA interference company developing medicines that silence disease-causing genes. Arrowhead's wholly owned portfolio is led by REDEMPLO (plozasiran) in triglyceride disorders, with additional cardiometabolic programs in obesity, MASH and homozygous familial hypercholesterolemia.
Positive Phase 3 SHASTA-3 and SHASTA-4 data shift the near-term question from clinical efficacy to regulatory and commercial conversion. The sHTG filing, label and payer adoption will determine whether REDEMPLO develops into a broader cardiometabolic franchise.
The market may focus on headline triglyceride reduction. Clinaptis considers threshold crossing below 500 mg/dL, pancreatitis outcomes, quarterly dosing and access relative to TRYNGOLZA more important to differentiation.
Whether positive SHASTA-3 and SHASTA-4 data convert into a timely sHTG label and durable REDEMPLO adoption
Plozasiran · Supplemental NDA submission for severe hypertriglyceridemia · By year-end 2026
4 assets · 4 programs
Tryngolza’s approval changes the question ahead of SHASTA-3/4. The Street will focus on headline TG reduction; we think the real readout is threshold crossing below 500 mg/dL.
